Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (teriparatide): Switching from Antiresorptive

A wash out period between end of antiresorptive treatment and start of Forsteo is not required. A particular recommendation for switching is not available and the decision remains at the discretion of prescribing physician.

Further information

Decisions regarding when to initiate a new treatment are up to the discretion of the physician, incorporating clinical judgment according to institutional guidelines and/or clinical practice.

Forsteo is not indicated in combination with an antiresorptive.1

Treatment with an antiresorptive should be discontinued before initiating Forsteo, since the clinical benefit of using teriparatide in combination with a bisphosphonate or denosumab has not been established.

References

1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: November 14, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question